SET and MYND domain containing 1Genealiases: BOP · KMT3D · ZMYND18 · ZMYND22
Q-omics provides the consensus-scored SMYD1 profile across patient tissues and cancer cell-line models. SMYD1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, SMYD1 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, SMYD1 protein abundance shows 14,371 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight HNSC as cancer lineages where SMYD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SMYD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SMYD1 survival associations across molecular data types. SMYD1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SMYD1 RNA expression–survival associations across cancer types. High SMYD1 expression shows unfavorable associations in HNSC, MESO, KIRC, THCA and KIRP, but favorable associations in STAD. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for SMYD1 RNA expression.
This table summarizes SMYD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for SMYD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SMYD1 shows lower tumor expression in HNSC, COAD, BRCA, STAD, READ and KICH. The HNSC box plot shows higher SMYD1 RNA expression in normal versus tumor tissue (log2 FC = −2.028, t-test p = .002).
This table shows molecular features associated with SMYD1 in patient tissues and cancer cell lines. In patient samples, SMYD1 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, SMYD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and SOFT_TISSUE.
